CJC-1295 / Ipamorelin
A GHRH analog paired with a selective ghrelin-receptor agonist, studied together for pulsatile growth-hormone signaling.
Overview
This is a combination of two distinct research peptides commonly studied together: CJC-1295, a modified analog of growth-hormone-releasing hormone (GHRH), and Ipamorelin, a selective growth-hormone secretagogue that mimics the hormone ghrelin. They act on different receptors within the growth-hormone axis, which is why they are frequently studied as a pair rather than individually.
Mechanism of Action
CJC-1295 binds GHRH receptors in the pituitary gland, extending the natural pulsatile release of growth hormone. Ipamorelin binds ghrelin receptors, triggering an additional, more selective GH pulse, with comparatively little effect on cortisol or prolactin compared to older-generation secretagogues examined in earlier literature. Combined, preclinical research has examined whether the two produce a synergistic pulsatile GH-release pattern greater than either alone.
Cited Research
GHRH-analog stability research
Studied structural modifications (including DAC and non-DAC forms) developed to extend CJC-1295’s half-life relative to native GHRH.
Ghrelin-receptor selectivity
Characterized Ipamorelin’s selectivity for the ghrelin receptor compared to earlier-generation growth-hormone-releasing peptides.
Pulsatile GH-release combination studies
Examined the combined effect of GHRH-analog and ghrelin-receptor-agonist administration on growth-hormone pulse amplitude.
IGF-1 signaling research
Explored resulting changes in insulin-like growth factor 1 (IGF-1) as a downstream marker of GH-axis activation.
This is a summary, not an exhaustive review. Search the primary literature yourself: CJC-1295 & Ipamorelin on PubMed →
Safety & Handling
Both peptides should be handled only by qualified personnel in a laboratory setting, stored and reconstituted per their Certificates of Analysis, and kept refrigerated once reconstituted. Neither is evaluated or approved by the FDA for any human or veterinary use.
Frequently Asked Questions
Why are these two peptides studied together?
They act on two different receptors in the same hormonal pathway, so researchers often combine them to study whether the combination produces a more pronounced pulsatile GH-release pattern than either compound alone.
Is this combination legal to purchase?
Both are legal to sell and purchase as research chemicals for laboratory use in the U.S. Neither is approved by the FDA as a drug or supplement for human consumption.
How should it be stored?
Keep the lyophilized powder refrigerated or frozen prior to reconstitution. Once reconstituted, keep refrigerated and use within the timeframe on the Certificate of Analysis.
Is this page medical advice?
No. This page summarizes published literature for research and educational context only. It does not recommend a dose, protocol, or use in humans or animals outside a laboratory setting.
Have a specific question about CJC-1295 / Ipamorelin?
Ask Signal IQ Rx — our research assistant trained on the Signal Library.